Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia

Open access

Abstract

Introduction: Synapse dysfunction is emerging as an early pathological event in frontotemporal dementia (FTD), however biomarkers are lacking. We aimed to investigate the value of cerebrospinal fluid (CSF) neuronal pentraxins (NPTXs), a family of proteins involved in homeostatic synapse plasticity, as novel biomarkers in genetic FTD. Methods: We included 106 presymptomatic and 54 symptomatic carriers of a pathogenic mutation in GRN,C9orf72 or MAPT, and 70 healthy non-carriers participating in the Genetic Frontotemporal dementia Initiative (GENFI), all of whom had at least one CSF sample. We measured CSF concentrations of NPTX2 using an in-house ELISA, and NPTX1 and NPTX receptor (NPTXR) by Western blot. We correlated NPTX2 with corresponding clinical and neuroimaging datasets as well as with CSF neurofilament light chain (NfL) using linear regression analyses. Results: Symptomatic mutation carriers had lower NPTX2 concentrations (median 643 pg/mL, IQR (301–872)) than presymptomatic carriers (1003 pg/mL (624–1358), p<0.001) and non-carriers (990 pg/mL (597–1373), p<0.001) (corrected for age). Similar results were found for NPTX1 and NPTXR. Among mutation carriers, NPTX2 concentration correlated with several clinical disease severity measures, NfL and grey matter volume of the frontal, temporal and parietal lobes, insula and whole brain. NPTX2 predicted subsequent decline in phonemic verbal fluency and Clinical Dementia Rating scale plus FTD modules. In longitudinal CSF samples, available in 13 subjects, NPTX2 decreased around symptom onset and in the symptomatic stage. Discussion: We conclude that NPTX2 is a promising synapse-derived disease progression biomarker in genetic FTD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jnnp-2019-322493

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 NPTX2 levels (A) in presymptomatic (n=106) and symptomatic mutation carriers (n=54) and non-carriers (n=70) and (B) separated by genetic group. Whiskers indicate minimum and maximum values. Orange squares indicate subjects who converted to the symptomatic stage during follow-up (n=3); grey asterisks indicate subjects with amyotrophic lateral sclerosis (ALS) without frontotemporal dementia (FTD) (n=3); grey crosses indicate subjects with both FTD and ALS (n=4). P values are from analyses of covariance (ANCOVAs) with age as a covariate and Bonferroni correction for multiple comparisons. *p<0.05; **p<0.01; ***p<0.001. CSF, cerebrospinal fluid; NPTX, neuronal pentraxin; PRE, presymptomatic mutation carrier; SYM: symptomatic mutation carrier.
Figure 1 NPTX2 levels (A) in presymptomatic (n=106) and symptomatic mutation carriers (n=54) and non-carriers (n=70) and (B) separated by genetic group. Whiskers indicate minimum and maximum values. Orange squares indicate subjects who converted to the symptomatic stage during follow-up (n=3); grey asterisks indicate subjects with amyotrophic lateral sclerosis (ALS) without frontotemporal dementia (FTD) (n=3); grey crosses indicate subjects with both FTD and ALS (n=4). P values are from analyses of covariance (ANCOVAs) with age as a covariate and Bonferroni correction for multiple comparisons. *p<0.05; **p<0.01; ***p<0.001. CSF, cerebrospinal fluid; NPTX, neuronal pentraxin; PRE, presymptomatic mutation carrier; SYM: symptomatic mutation carrier.CC BY · PubMed Central
Figure 2 Relationship between NPTX2 and (A) frontal lobe volume (n=126), (B) insular volume (n=126), (C) Mini Mental State Examination (MMSE) (n=145) and (D) Clinical Dementia Rating scale (CDR) plus FTD modules (n=120) among mutation carriers. b and p were obtained through multiple linear regression with square-root transformed NPTX2 as the dependent variable, adjusting for age, gender and study site; for MMSE, we also included years of education as a covariate. CSF, cerebrospinal fluid; FTD, frontotemporal dementia; NPTX, neuronal pentraxin; TIV, total intracranial volume.
Figure 2 Relationship between NPTX2 and (A) frontal lobe volume (n=126), (B) insular volume (n=126), (C) Mini Mental State Examination (MMSE) (n=145) and (D) Clinical Dementia Rating scale (CDR) plus FTD modules (n=120) among mutation carriers. b and p were obtained through multiple linear regression with square-root transformed NPTX2 as the dependent variable, adjusting for age, gender and study site; for MMSE, we also included years of education as a covariate. CSF, cerebrospinal fluid; FTD, frontotemporal dementia; NPTX, neuronal pentraxin; TIV, total intracranial volume.CC BY · PubMed Central
Figure 3 Correlation between NPTX2 and NfL levels in presymptomatic (n=106) and symptomatic (n=50) mutation carriers. NfL is plotted on a log-scale for visualisation purposes. b and p were obtained through multiple linear regression with square-root transformed NPTX2 as the dependent variable, adjusting for age, gender and study site. CSF, cerebrospinal fluid; NfL, neurofilament light chain; NPTX, neuronal pentraxin.
Figure 3 Correlation between NPTX2 and NfL levels in presymptomatic (n=106) and symptomatic (n=50) mutation carriers. NfL is plotted on a log-scale for visualisation purposes. b and p were obtained through multiple linear regression with square-root transformed NPTX2 as the dependent variable, adjusting for age, gender and study site. CSF, cerebrospinal fluid; NfL, neurofilament light chain; NPTX, neuronal pentraxin.CC BY · PubMed Central
Figure 4 Longitudinal NPTX2 levels plotted against age in 13 subjects with multiple CSF samples. A line is drawn between NPTX2 levels of follow-up samples. Presymptomatic samples are shown as green squares, symptomatic samples as red triangles and the non-carrier as blue circles. GRN mutation carriers are shown as open symbols, C9orf72 mutation carriers as filled symbols and the MAPT mutation carrier as half-filled symbols. Dotted horizontal line indicates median NPTX2 level in presymptomatic mutation carriers (1003 pg/mL); dashed horizontal line indicates median in symptomatic mutation carriers (644 pg/mL). For blinding purposes, a jitter of ±2 years was applied to all subjects. CSF, cerebrospinal fluid; NPTX, neuronal pentraxin.
Figure 4 Longitudinal NPTX2 levels plotted against age in 13 subjects with multiple CSF samples. A line is drawn between NPTX2 levels of follow-up samples. Presymptomatic samples are shown as green squares, symptomatic samples as red triangles and the non-carrier as blue circles. GRN mutation carriers are shown as open symbols, C9orf72 mutation carriers as filled symbols and the MAPT mutation carrier as half-filled symbols. Dotted horizontal line indicates median NPTX2 level in presymptomatic mutation carriers (1003 pg/mL); dashed horizontal line indicates median in symptomatic mutation carriers (644 pg/mL). For blinding purposes, a jitter of ±2 years was applied to all subjects. CSF, cerebrospinal fluid; NPTX, neuronal pentraxin.CC BY · PubMed Central
Figure 5 NPTX1 and NPTXR levels as measured by Western blot. (A) Representative (cropped) Western blots of NPTX1 and NPTXR (n=230); (B, C) NPTX1 and NPTXR levels across groups, expressed as a percentage of band intensity compared with non-carriers. Whiskers indicate minimum and maximum values. Displayed significance levels are from analysis of covariance (ANCOVA) on square-root transformed relative band intensities of NPTX1 and NPTXR with age as a covariate. *p<0.05; **p<0.01. CSF, cerebrospinal fluid; NPTX, neuronal pentraxin; PRE, presymptomatic mutation carrier; SYM, symptomatic mutation carrier.
Figure 5 NPTX1 and NPTXR levels as measured by Western blot. (A) Representative (cropped) Western blots of NPTX1 and NPTXR (n=230); (B, C) NPTX1 and NPTXR levels across groups, expressed as a percentage of band intensity compared with non-carriers. Whiskers indicate minimum and maximum values. Displayed significance levels are from analysis of covariance (ANCOVA) on square-root transformed relative band intensities of NPTX1 and NPTXR with age as a covariate. *p<0.05; **p<0.01. CSF, cerebrospinal fluid; NPTX, neuronal pentraxin; PRE, presymptomatic mutation carrier; SYM, symptomatic mutation carrier.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

12 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 107

Metadata

Authors
van der Ende, E. L., Xiao, M., Xu, D., Poos, J. M., Panman, J. L., Jiskoot, L. C., Meeter, L. H., Dopper, E. G., Papma, J. M., Heller, C., Convery, R., Moore, K., Bocchetta, M., Neason, M., Peakman, G., Cash, D. M., Teunissen, C. E., Graff, C., Synofzik, M., Moreno, F., Finger, E., Sánchez-Valle, R., Vandenberghe, R., Laforce Jr, R., Masellis, M., Tartaglia, M. C., Rowe, J. B., Butler, C. R., Ducharme, S., Gerhard, A., Danek, A., Levin, J., Pijnenburg, Y. A., Otto, M., Borroni, B., Tagliavini, F., de Mendonca, A., Santana, I., Galimberti, D., Seelaar, H., Rohrer, J. D., Worley, P. F., & van Swieten, J. C.
Affiliations
  • Johns Hopkins University (US)
  • Erasmus MC (NL)
  • Leiden University Medical Center (NL)
  • University College London (GB)
  • UCL Queen Square Institute of Neurology (GB)
  • Amsterdam Neuroscience (NL)
  • Karolinska University Hospital (SE)
  • German Center for Neurodegenerative Diseases (DE)
  • Western University (CA)
  • KU Leuven (BE)
  • Sunnybrook Health Science Centre (CA)
  • University of Toronto (CA)
  • University of Cambridge (GB)
  • University of Oxford (GB)
  • Montreal Neurological Institute and Hospital (CA)
  • Klinik und Poliklinik für Neurologie (DE)
  • Universität Ulm (DE)
  • University of Brescia (IT)
  • Istituti di Ricovero e Cura a Carattere Scientifico (IT)
  • Centro de Neurociências e Biologia Celular (PT)
  • University of Milan (IT)
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2020-04-09
Volume
91
Issue
6
Pages
612-621
ISSN
  • 0022-3050 (ISSN-L)
  • 1468-330X
OpenAlex
W3015522591
Cited by
94
References
45
Citations by year
2026: 7 · 2025: 20 · 2024: 17 · 2023: 15 · 2022: 16 · 2021: 15 · 2020: 4
FWCI
9.12
Type
journal article
Language
en
Open access
Locations
  • Journal of Neurology Neurosurgery & Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • Institutional Research Information System (Università degli Studi di Trento) (submittedVersion, cc-by)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • DZNE Pub (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Apollo
Funders
  • Deutsche Forschungsgemeinschaft
  • Horizon 2020 Framework Programme (779357)
  • Schorling foundation
  • NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH)
  • Stockholms Läns Landsting
  • Munich Cluster for Systems Neurology (EXC 2145 SyNergy 390857198)
  • Swedish Demensfonden
  • Swedish FTD Initiative
  • The Bluefield Project to Cure Frontotemporal Dementia
  • Stichting Dioraphte (1402 1300)
  • Swedish Alzheimer Foundation
  • Stiftelsen för Gamla Tjänarinnor
  • Vetenskapsrådet (2015-02926, 2018-02754, 529-2014-7504)
  • Hjärnfonden
  • MRC UK (MR/M023664/1)
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (733050103, 733050813)
  • Alzheimer Nederland (733050103, 733050813)
  • StratNeuro
  • European Joint Programme - Neurodegenerative Disease Research (733051024, 733051042)
  • Mady Browaeys Fonds voor Onderzoek naar Frontotemporale Degeneratie
  • Karolinska Institutet Doctoral funding
  • Fundacio Marato de TV3 (20143810)
  • MRC Clinician Scientist Fellowship (MR/M008525/1)
  • Wellcome Trust (103838)
  • Alzheimer's Society (As-PhD-2015-005)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
NPTX2, NPTX1, cerebrospinal fluid biomarkers, genetic frontotemporal dementia, presymptomatic mutation carriers, synaptic dysfunction, neurofilament light chain, gray matter volume, disease progression, phonemic fluency, Clinical Dementia Rating
MeSH terms
Pentraxins, Adult, Aged, C-Reactive Protein, Female, Heterozygote, Humans, Male, Middle Aged, Nerve Tissue Proteins, Biomarkers, Neurofilament Proteins, Disease Progression, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. https://app.cochat.ai/papers/10.1136/jnnp-2019-322493
The paper
van der Ende, E. L., Xiao, M., Xu, D., Poos, J. M., Panman, J. L., Jiskoot, L. C., Meeter, L. H., Dopper, E. G., Papma, J. M., Heller, C., Convery, R., Moore, K., Bocchetta, M., Neason, M., Peakman, G., Cash, D. M., Teunissen, C. E., Graff, C., Synofzik, M., . . . van Swieten, J. C. (2020). Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2019-322493

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.